Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients

Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R,
Altmeyer A, Csermak-Renner K, McGrath L, Lantwicki L, Hohneker JA.
Critical review: Updated recommendations for the prevention,
diagnosis, and treatment of osteonecrosis of the jaw in cancer
patients-May 2006.
Crit Rev Oncol Hematol. 2007 May;62(2):148-52. Epub 2007 Mar 1.
PMID: 17336086 [PubMed - in process]
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=17336086&dopt=Abstract>

Novartis Pharmaceuticals Corporation, East Hanover, NJ,
United States.

In light of recent reports of osteonecrosis of the jaw (ONJ)
in cancer patients whose treatment regimens include an
intravenous bisphosphonate, Novartis convened an
international advisory board of experts in the fields of oral
surgery and pathology, medical oncology, metabolic bone
disease, and orthopedics to review existing data and provide
updated recommendations on the clinical diagnosis,
prevention, and management of ONJ in the oncology setting.
Recommendations were developed to help guide healthcare
professionals in early diagnosis and patient management. It
is recommended that patients be encouraged to receive a
dental examination prior to initiating bisphosphonate therapy
and, if possible, complete any necessary dental procedures
(e.g., tooth extraction) prior to initiating bisphosphonate
therapy. Patients should receive regular dental visits during
bisphosphonate therapy. Patients should be encouraged to
practice good oral hygiene and minimize possible jaw trauma.
If possible, patients should avoid dental surgery during
treatment with bisphosphonates. If exposed bone is observed
or reported in the oral cavity at any time (suspected ONJ),
refer the patient to a dental professional immediately.

--
Matti Narkia
.

Relevant Pages

  • Re: Elan shares jump 25% on Tysabri news.
    ... Committee recommendations, and what they might mean for those patients ... An FDA advisory committee today recommended that Tysabri (natalizumab, ...
    (alt.support.mult-sclerosis)
  • Re: RA Treatment Guidelines
    ... June 26 -- New recommendations for the use ... The recommendations on the use of non-biologic and biologic DMARDs in ... Arthritis Care & Research, also take into account RA disease duration, ... Methotrexate plus hydroxychloroquine is endorsed for patients with ...
    (alt.support.arthritis)
  • Re: Nutrition Recommendations and Interventions for Diabetes-2006
    ... It would not work because 90% of the patients ... If I couldn't keep tight control at that level I would add metformin. ... be better guidelines for the treatment of those who ARE ... would be happier with your recommendations. ...
    (alt.support.diabetes)
  • Re: Hashing for big list of last names
    ... Any recommendations on the hashing type (chaining, ... list of last names of Patients from a CSV file which is a very ...
    (comp.programming)
  • Re: Natalizumab Withdrawal Linked to Significant Lesion Increase In...
    ... This is an interesting article from a usually reliable source. ... of partial immunosuppression giving rise to extra disease activity has ... "For now the recommendations remain the same - patients and their ...
    (alt.support.mult-sclerosis)